• 05.Nov 2018 | Company news |

    EPO at 30th EORTC-NCI-AACR Conference

    Molecular Targets Cancer Therapeutics 13. – 16. Nov 2018 Dublin

    Dr. Behrens provided information about the development of new models for pancreatic cancer and how to evaluate combination therapies in preclinical models. The described PDX panel clearly reflects clinical pancreatic cancer histology, growth and inherent and acquired treatment resistance as well as recurrent disease.

    For more details see newsletter Nov 2018

  • 05.Sep 2018 | Company news |

    Citoxlab signs investment and partnership deal with Experimental Pharmacology and Oncology Berlin-Buch GmbH (EPO)

    Investment in the German CRO, specialized in the preclinical assessment of new anticancer drugs, strengthens Citoxlab’s pharmacology portfolio, which will benefit from many synergies with preclinical safety and biomarkers services already provided by Citoxlab

    Evreux, France and Berlin, Germany, September 3, 2018 – Citoxlab, a leading CRO for non-clinical research, today announces an investment and partnership deal with Experimental Pharmacology and Oncology Berlin-Buch GmbH (EPO), a well-recognized CRO providing comprehensive services for preclinical oncology research worldwide.

    Founded in 1997, EPO is an AAALAC accredited organization. It provides in vitro and in vivo testing of drug candidates with antitumoral and/or immunostimulatory activities in the oncology field. With state-of-the art facilities of 1,300m2 (12,000ft2) at the Campus Berlin-Buch, EPO offers, in particular, a comprehensive range of well characterized syngeneic tumor models, Patient Derived Xenograft (PDX) models and humanized tumor models. More than one hundred large pharma and biotech companies from Europe, Asia and North America have already used EPO’s services.

    Dr. Jean-François Le Bigot, president and CEO of Citoxlab Group said: “We are particularly happy that EPO’s management agreed to our investment proposal. Its scientific reputation and the reliability of its studies are widely recognized in the oncology community. More than 40% of the new drugs under development target cancer. Offering an integrated services portfolio which includes pharmacology alongside drug safety, pharmacokinetics and bioanalysis/biomarkers will allow Citoxlab-EPO’s clients to save time and money and avoid the risks linked to moving from one CRO to another. Several key clients have already told us that this integrated-services offering perfectly meets their needs. For biotechnology companies, financial milestones are often linked to reaching specific development steps, so integrated operations optimizing time spent can be a strategic advantage.”

    Dr. Jens Hoffman, CEO of EPO said: “As the founders and main shareholders, Dr. Iduna Fichner, Prof. Dr. Wolfgang Walther, CSO, and myself have carefully analyzed Citoxlab’s interest in our company, with our long-term development in mind. As one of the top five non-clinical CROs worldwide, Citoxlab has established long-lasting business relationships with hundreds of customers. In addition, as a science driven CRO, Citoxlab has developed specialties in disciplines such as immunohistochemistry, cell cytometry and genomics, which are key in our area of research. We believe that these scientific synergies, combined with Citoxlab’s strong business development dynamics, will benefit both us and our clients. I must add that the respect for the culture and management in their previous acquisitions shown by Citoxlab was important in choosing this strategic partnership, where Citoxlab will own 49% of EPO.”

    About EPO
    Experimental Pharmacology and Oncology Berlin-Buch GmbH (EPO) is one of the leading contract research organizations (CRO) providing comprehensive worldwide services for preclinical oncology research. EPO is specialized in the development of tailored basic and translational research models to support drug development, starting with target validation and compound screening and ending in integrational in vivo studies addressing pharmacology, pharmacokinetics, biomarkers and tolerability. EPO has established models for radiation and immune oncology research. EPO’s operations meet the highest industrial standards endorsed by more than one hundred customers worldwide. Its highly motivated and qualified team guarantees short response times, consistency of service, regular updates and transparency. EPO is based at the Campus Berlin-Buch, one of Germany´s leading biotech locations.

    About Citoxlab Group
    With nine facilities located in France (Evreux and Saint-Nazaire), Canada (Laval and Boisbriand), the US (Kansas City), Denmark (Copenhagen) and Hungary (Veszprém, Budapest, Szeged), Citoxlab Group offers a comprehensive range of preclinical services to meet the needs of pharmaceutical, biotechnology, medical device, chemical and agrochemical companies worldwide. Citoxlab carries out studies in general and reproductive toxicology, carcinogenicity, immunology, pharmacology, pharmacokinetics and bioanalysis/biomarkers. Citoxlab and Atlanbio also offer both preclinical and clinical bioanalysis and biomarker services. AccelLAB provides efficacy and safety studies of medical devices (cardiology, ENT, orthopedics and regenerative medicine). In partnership with Stemina (Madison, USA) the Group offers screening services using human embryonic stem cell models. With the recently acquired Solvo Biotechnology, products and services in the field of transporters and DDI are now available. Today, Citoxlab has 1,400 employees working at nine sites with state-of-the-art facilities, generating revenues of €150M ($175M). The company has a world-class top-level management team in scientific, financial and business activities.
    www.citoxlab.com

  • 29.March 2018 | Company news |

    EPO joined the AACR Annual Meeting 2018 "Driving Innovative Cancer Science to Patient Care" in Chicago

    between April 14-18.2018

    If you are interested in special approaches or technologies of EPO, please have a look at our posters.

    Poster #1145 / 2 .............. (Download Poster-1145.pdf)
    Humanized immune-PDX mouse models for 10 different tumor entities in translational immuno-oncology research


    Poster #1040 / 13 ............ (Download Poster-1040.pdf)
    Patient derived xenografts of hematologic malignancies for translational research


    Poster #4093 / 21 ............. (Download Poster-4093.pdf)
    Preclinical evaluation of novel treatment strategies in patient-derived xenograft (PDX) models of pancreatic cancer

  • 18.October 2017 | Company news |

    EPO presented two posters with new data of selected topics at AACR-NCI-EORTC International Conference in Philadelphia

    Poster #A005
    Drug screening in patient-derived xenografts from acute myeloic leukemia and non-Hodgkin's lymphoma shows correlation with chemotherapy resistance in patients
    The poster will be presented in Poster Session A "Animal Models"
    on Saturday October 28, 2017 12:30 - 4:00 pm
    In Hall E, Pennsylvania Convention Center, Poster Board number 5;
    Abstract #270-Go to online version...

    Poster #A006
    Preclinical tumor models in humanized mice for translational immuno-oncology research
    The poster will be presented in Poster Session A "Animal Models"
    on Saturday October 28, 2017 12:30 - 4:00 pm
    In Hall E, Pennsylvania Convention Center, Poster Board number 6;
    Abstract # 272 - Go to online version...

  • 27.July 2017 | Company news |

    AAALAC accreditation for EPO

    EPO received the full accreditation of AAALAC International, a non-profit organization, that promotes responsible laboratory work with highest quality, scientific, and ethical standards through an accreditation program. This major achievement enables us to provide our service following the best up to date rules and conditions in a strictly controlled way.

    For more details see newsletter October 2017.

  • 14.May 2017 | Company news |

    EPO joined the AACR Annual Meeting 2017 in Washington, D.C. and presented there three posters with impressive consideration.

    Poster #1697
    Humanized immune-oncology mouse models
    Go to online version...

    Poster #1843
    Intratumoral heterogeneity of renal cancer is related to differences in drug response and development of therapy resistance.
    Go to online version ...

    Poster #4943
    Orthotopic transplantation of pancreatic cancer PDX models increases murine stroma content, but does not influence therapeutic response to standard of care.
    Go to online version ...

  • 10.February 2017 | Company press release |

    Tracking resistance - new tumor models predict treatment response to anticancer drugs in colon carcinomas

    Together with international colleagues scientists from Berlin found new genetic patterns, which help to predict response in colon cancer.

    go to press release

  • 05.01.2016 | Company news

    January 2016 - EPO collaboration with NexusPharma

    EPO starts strategic collaboration with NexusPharma to foster its market position in the USA.
    see press release ...

  • 05.01.2016 | Company news

    January 2016 - Histopatology service at EPO

    EPO announces a comprehensive histopatology service for experimental in vivo studies. The independent department offers custom-oriented necropsies, tissue processing, preparation of sections, any (immuno) histological staining and evaluation.

Newsletter Login / Logout

Newsletter - November 2018:

EPO at 30th EORTC-NCI-AACR Conference in Dublin
Molecular Targets Cancer Therapeutics 13. – 16. Nov 2018 Read more ...

Newsletter - September 2018:

Citoxlab signs investment and partnership deal with EPO!
Read more ...

Newsletter - March 2018:

EPO@AACR Annual Meeting 2018 in Chicago ... April 14-18.2018
Read more (link)

Newsletter - October 2017:

EPO -October 26-30.2017
AACR-NCI-EORTC International Conference in Philadelphia ...
Read more (link)

EPO received full AAALAC accreditation ...
Read more (link)

Newsletter - September 2017:

EPO offers comprehensive support in the preclinical development of biosimilars ...
Read more (link)

Newsletter - March 2017:

EPO at AACR Annual Meeting 2017 in Washington, D.C.
Read more (link)

Newsletter 4:

EPO has developed a large panel of glioma PDX models. Some of them are growing as orthotopic tumors enabling highly sophisticated studies.
Read more (link)

Newsletter 3:

EPO offers ultrasound imaging for the monitoring of tumor growth.
Read more (link)

Newsletter 2:

EPO has available facilities and device for the use of irradiation in vitro and in vivo.
Read more (link)

Newsletter 1:

Besides expertise for the determination of antitumor efficacy EPO has available special technologies for imaging, radiation, biomarker analysis at protein and molecular level.
Here are some examles (link)

Newsletter - Archiv

2017 © EPO Berlin-Buch GmbH